Skip to main content

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In two clinical trials, 1227 subjects were treated with JUBLIA, 1161 for at least 24 weeks and 780 for 48 weeks. Adverse reactions reported within 48 weeks of treatment and in at least 1% of subjects treated with JUBLIA and those reported in subjects treated with the vehicle are presented in Table 1.

Table 1: Adverse Reactions Reported by at Least 1% of Subjects Treated for up to 48 Weeks

Adverse Event, n (%) JUBLIA
N = 1227
N = 413
Ingrown toenail 28(2.3%) 3(0.7%)
Application site dermatitis 27(2.2%) 1 (0.2%)
Application site vesicles 20 (1.6%) 0 (0.0%)
Application site pain 13(1.1%) 1 (0.2%)